Презентация на тему "Food & Drug Administration"

Содержание

• 
  Слайд 1
  
• 
  Слайд 2
  

  Food & Drug Administration (FDA) 1862, started with a single chemist in the USDA 1927, Bureau of Chemistry changed to the Food, Drug, & Insecticide Administration 1930, name was shortened to the present version 2001, staff ~9,100 employees & a budget of $1.3 billion

• 
  Слайд 3
  

  Adulteration and misbranding of foods & drugs have always been a problem in the U.S. The problem increased by the late 19th C. Drugs such as Quinine were cut with fillers to increase profit Sufferers of serious illnesses were sold worthless drugs or therapies Preservatives added to foods & drugs were useless or worse toxic

• 
  Слайд 4
  

  http://www.fda.gov/cder/about/history/Graphics/OilKingLrg.jpg

• 
  Слайд 5
  

  http://www.fda.gov/cder/about/history/Gallery/gallery21.htm

• 
  Слайд 6
  

  Harvey Washington Wiley, chief chemist concerned about chemical preservatives, initiated "poison squad" experiments Healthy volunteers consumed varying amounts of questionable food additives to determine their impact on health Officially designated the “Hygienic Table.” Chemicals fed to the young men included borax, salicylic, sulfurous, and benzoic acids, & formaldehyde

• 
  Слайд 7
  

  Wiley became convinced that chemical preservatives should be used in food only when necessary That the burden of proving safety should fall on the producer That none should be used without informing the consumer on the label Wiley unified a variety of groups behind a federal law to prohibit the adulteration and misbranding of food and drugs

• 
  Слайд 8
  

  Food and Drugs Act of 1906 First nationwide consumer protection law made it illegal to distribute misbranded or adulterated foods, drinks and drugs across state lines Offending products could be seized & condemned; persons could be fined & jailed Drugs had either to abide by standards of purity and quality set forth in the UNITED STATES PHARMACOPEIA & the NATIONAL FORMULARY Presence & quantity of alcohol or certain narcotic drugs had to be stated on proprietary labels

• 
  Слайд 9
  

  There were however, shortcomings in the 1906 law Law prevented blatant fraud, but it did not prevent deception Numerous examples of foods deceptively packaged or labeled began to show up The law also did not insist that products be tested for safety

• 
  Слайд 10
  

  http://www.fda.gov/oc/history/slideshow/Slide_182_139.html Flavoring Extract Bottle thick glass obscures how much expensive flavoring extract is really in the bottle

• 
  Слайд 11
  

  Lash-Lure, an eyelash dye that blinded many women http://www.fda.gov/oc/history/

• 
  Слайд 12
  

  A disaster in 1937 prompted Congress to act A Tennessee drug company marketed a form of the new sulfa wonder drug that would appeal to pediatric patients, Elixir Sulfanilamide The solvent in this untested product was diethylene glycol Over 100 people died, many of whom were children

• 
  Слайд 13
  

  http://www.fda.gov/cder/about/history/Page18.htm Elixir Sulfanilamide

• 
  Слайд 14
  

  1938 Federal Food, Drug, and Cosmetic Act For the first time, required companies to prove the safety of new drugs before putting them on the market Over the years new responsibilities were added including the requirement that drugs and medical devices be proven effective as well as safe before they can be sold

• 
  Слайд 15
  

  Currently the FDA is charged with: Safeguarding the nations food supply, by ensuring that all ingredients used in foods are safe, & that food is free of contaminants Approves all new food additives before they can be used Monitors the safety of dietary supplements & the content of infant formulas & medical foods Protects the public from unnecessary exposure to radiation from electronic products. (microwave ovens, cell phones, x-ray equipment, lasers, medical ultrasound & MRI machines) Monitors cosmetic products to be sure that they are safe & properly labeled

• 
  Слайд 16
  

  Medical products need to be proven safe and effective before they can be used by patients The product categories covered by this requirement include: Medicines used for the treatment and prevention of disease Biologics, vaccines, blood products, biotechnology products and gene therapy Medical Devices, FDA regulates all medical devices, from very simple items like tongue depressors or thermometers to very complex technologies such as heart pacemakers and dialysis machines.

• 
  Слайд 17
  

  Drug Review & Approval

• 
  Слайд 18
  
• 
  Слайд 19
  

  The majority of prospective new drugs fail testing, many never make it passed the pre-clinical stage The pre-clinical stage involves testing in either animals or cells and looks at the potential drugs efficacy in a model of the the disease This stage also involves looking for possible toxicity or side-effects that may be significant if the compound moves ahead to human studies

• 
  Слайд 20
  

  If a compound shows promise during the pre-clinical phase the drug maker may decide to move forward with human testing Human testing of a drug is known as a clinical trial For a drug to be tested in humans the Sponsor must submit an application to The Center for Drug Evaluation and Research (CDER), part of the FDA This application is known as an Investigational New Drug Application (IND)

• 
  Слайд 21
  

  Investigational New Drug Application (IND) The IND is reviewed by both the FDA and a local IRB An Institutional Review Board (IRB) is a panel of physicians, scientists, & lay persons who oversee research done using humans Each hospital or research institution must have an IRB if it allows human research The IRB approves the clinical trial protocols, these describe who may participate in the trial, the schedule of tests and procedures, the medications and doses, the study’s length, and finally its objectives

• 
  Слайд 22
  

  After approval by the IRB and the FDA, clinical trials can begin There are up to four different phases of trials, each with a specific objective. If any problems arise during any of these phases the FDA is notified and the IND application is canceled

• 
  Слайд 23
  

  Phase I Studies Conducted in healthy volunteers, between 20 to 80 Goal is to determine safety and look for possible side effects The studies are usually open-label meaning the volunteers & the physicians know who is getting the drug The Pharmacokinetics of the drug is often investigated If no unacceptable toxicity is revealed, phase II studies can be initiated

• 
  Слайд 24
  

  Phase II Studies Shift in emphasis from safety to effectiveness Collection of preliminary data on whether the drug works in people who have a certain disease or condition Usually two groups of patients are compared, one group receiving the drug is compared to a second group who receives either a placebo or a different drug Studies are often done in the double blind method, this means the neither the patient, physician, nor the drug company know which patients are getting the drug & which are getting the placebo The number of subjects rages from a few dozen to 300

• 
  Слайд 25
  

  Phase III Studies If effectiveness is shown during phase II the study is expanded to a phase III The goal during this phase is the continued collection of safety and effectiveness data These data are collected on a larger population that is more varied than that studied during phase II Phase III also often studies the drug at different doses and in combination with other drugs The number of subjects ranges from a few hundred to a few thousand

• 
  Слайд 26
  

  Phase IV Studies Occur after a drug is approved Explore other aspects of the drug such as usage in new populations, such as children Long term effects are also explored Often after approval, some drugs are found to have unintended usages These are referred to as off-label uses It is legal for a physician to prescribe a drug for off-label use, but the drug company cannot advertise these uses until further studies are performed

• 
  Слайд 27
  

  New Drug Application (NDA) Once clinical trials are finished the sponsor places a formal request with the FDA to consider approving the drug This request is known as a New Drug Application (NDA) Once a NDA is filed the FDA has 60 days to review the application for filing If the FDA decides to file the application a review team of physicians, chemists, statisticians, microbiologist, and pharmacologists is assembled Only 1 in 5 drugs that enter clinical trials is ultimately approved by the FDA

• 
  Слайд 28
  

  Review Process The review team analyzes all aspects of the study results looking for possible problems, such a weaknesses in the study design or analyses Reviewers determine if they agree with the sponsor’s results and conclusions or if additional information is needed Each reviewer then prepares a written evaluation with their recommendation about the application

• 
  Слайд 29
  

  If the FDA decides that the benefits of the drug outweigh any risks the drug can then be marketed in the US If there are problems with the NDA, the FDA may decide that the drug is approvable or not approvable Approvable means that the drug may eventually be approved, but that some issues need to be resolved first Not approvable means there are significant problems that cannot be overcome without substantial additional data These could be safety problems or failure to demonstrate the drug’s effectiveness

• 
  Слайд 30
  

  Accelerated Approval Given to drugs for serious and life-threatening illnesses that lack satisfactory treatments Uses surrogate endpoints instead of traditional measures These can be laboratory findings that are not directly related to patient survival or function Most HIV drugs have been approved through this process with the provision that the companies continue to perform studies to confirm the drug’s ultimate benefit If future studies do not confirm initial results the FDA may withdraw approval

• 
  Слайд 31
  

  http://www.fda.gov/cder/handbook/develop.htm

• 
  Слайд 32
  

  Abbreviated New Drug Application (ANDA) Provides for the review and ultimate approval of a generic drug A generic drug is one that is comparable to an innovator drug in dosage form, strength, route of administration, quality, performance characteristics and intended use Termed abbreviated because they are generally not required to include preclinical and clinical data to establish safety and effectiveness Applicants must scientifically demonstrate that their product is bioequivalent

• 
  Слайд 33
  

  Bioequivalence In order to demonstrate bioequivalence scientists measure the time it takes the generic drug to reach the bloodstream in 24 to 36 healthy, volunteers This gives them the rate of absorption, or bioavailability, of the generic drug, which they can then compare to that of the innovator drug The generic version must deliver the same amount of active ingredients into a patient's bloodstream in the same amount of time as the innovator drug

• 
  Слайд 34
  

  Orphan Drugs In 1982 Congress passed the Orphan Drug Act The goal was to promote the development of products that demonstrate promise for the diagnosis and/or treatment of rare diseases or conditions More than 200 drugs & biological products for rare diseases have been brought to market since 1983 Prior to 1983 fewer than ten such products came to market

• 
  Слайд 35
  

  Adverse Events Reporting System (AERS) The FDA requires manufacturers to report adverse drug reactions Health care professionals & consumers can also send reports voluntarily through the MedWatch program If there are significant adverse effects the FDA may take regulatory actions to improve product safety and protect the public health Such as updating a product’s labeling information, sending out a "Dear Health Care Professional" letter, or re-evaluating an approval decision

• 
  Слайд 36
  

  If a drug has severe side effects, but is kept on the market a black box warning is placed on the label Recent black box warnings have been issued for: Advair/Serevent: small, but significant increase in asthma deaths particularily in African-Americans Depo-Provera: significant decrease in bone density Serzone: life-threatening liver failure All antidepressants for increased adolescent suicide Acetaminophen: life-threatening liver failure increased when taken with alcohol

• 
  Слайд 37
  

  Recent Drug Controversies Vioxx, voluntarily withdrawn due to increases in heart attacks & strokes Prempro, Premarin; hormone replacement therapy, a long term study showed increases in breast cancer & coronary heart disease Baycol (cerivastatin), removed from the market because of ~31 reports of fatal rhabdomyolysis, destruction of muscle tissue that can lead to kidney failure Crestor (Rosuvastatin) approved in August, 2003 has the same problem

• 
  Слайд 38
  

  If you have questions about medications your or your family are taking: http://www.fda.gov/medwatch/index.html

• 
  Слайд 39